The quarter witnessed strong revenue momentum, with net sales surging 17.07% sequentially to ₹4,030.59 crores from ₹3,442.93 crores in the previous quarter, whilst year-on-year growth stood at a healthy 12.89%. This marked the highest quarterly revenue in the company's history, reflecting sustained demand across its product portfolio and successful market penetration strategies. The pharmaceutical major, which commands significant presence in India's domestic formulations market, demonstrated operational resilience despite headwinds from elevated employee costs and margin pressures.
The results highlight a company navigating the delicate balance between aggressive growth investments and margin preservation. Whilst topline expansion remains robust, the compression in operating and net profit margins signals rising cost pressures, particularly in employee expenses and operational expenditure. The market's muted response reflects concerns about sustainability of margins in an increasingly competitive pharmaceutical landscape.
| Quarter | Net Sales (₹ Cr) | QoQ Growth | Net Profit (₹ Cr) | QoQ Growth | Operating Margin | PAT Margin |
|---|---|---|---|---|---|---|
| Jun'26 | 4,030.59 | +17.07% | 568.06 | +2.47% | 26.20% | 14.24% |
| Mar'26 | 3,442.93 | -3.48% | 554.35 | +35.62% | 27.01% | 16.25% |
| Dec'25 | 3,567.20 | -3.52% | 408.75 | -20.09% | 25.77% | 11.60% |
| Sep'25 | 3,697.16 | +3.55% | 511.51 | +16.70% | 24.92% | 14.07% |
| Jun'25 | 3,570.35 | +15.94% | 438.32 | +4.17% | 23.72% | 12.45% |
| Mar'25 | 3,079.37 | -3.73% | 420.77 | +10.66% | 22.19% | 13.93% |
| Dec'24 | 3,198.79 | — | 380.23 | — | 25.51% | 11.81% |
Financial Performance: Growth Momentum Tempered by Margin Compression
Mankind Pharma's Q1 FY27 financial performance presents a nuanced picture of strong revenue expansion accompanied by margin pressures. Net sales of ₹4,030.59 crores represented the company's highest-ever quarterly revenue, driven by robust demand across therapeutic segments and successful product launches. The sequential revenue growth of 17.07% was particularly impressive, reversing the declining trend observed in the previous two quarters.
However, profitability metrics revealed concerning trends. Operating profit (PBDIT excluding other income) stood at ₹1,056.19 crores, yielding an operating margin of 26.20%, down 81 basis points from 27.01% in Q4 FY26. This margin compression occurred despite revenue growth, indicating rising cost pressures. Employee costs surged to ₹913.50 crores in Q1 FY27, representing a substantial 21.54% sequential increase from ₹751.60 crores in the previous quarter, reflecting aggressive hiring and salary increments to support expansion plans.
The PAT margin contracted more sharply to 14.24% from 16.25% in Q4 FY26, a decline of 201 basis points. This was partly attributable to higher tax expenses, with the effective tax rate rising to 25.39% from 15.13% in the previous quarter. The normalisation of the tax rate after an unusually low rate in Q4 FY26 impacted bottom-line growth, though the company maintained healthy absolute profit levels.
Interest expenses continued their downward trajectory, declining to ₹109.98 crores from ₹141.75 crores in Q4 FY26, reflecting successful debt reduction efforts. The company's interest coverage ratio, measured by operating profit to interest, reached an impressive 9.60 times, the highest in recent quarters, demonstrating strong debt servicing capability. Depreciation remained relatively stable at ₹225.70 crores compared to ₹223.08 crores in the previous quarter.
Other income declined significantly to ₹45.00 crores from ₹114.29 crores in Q4 FY26, suggesting the previous quarter had benefited from one-time treasury gains or non-operating income. This decline in other income further pressured overall profitability metrics, though the core operating business remained fundamentally sound.
Operational Excellence: Capital Efficiency Under Pressure
Mankind Pharma's operational metrics reveal a company investing heavily for future growth whilst managing near-term efficiency challenges. The company's return on equity (ROE) averaged 15.98% over recent periods, a respectable figure indicating reasonable capital efficiency, though below the industry-leading standards set by peers like Torrent Pharma (23.24%). The latest ROE of 12.39% represents a decline from historical averages, reflecting the margin pressures and increased capital base following recent expansion activities.
Return on capital employed (ROCE) averaged 20.58% historically, demonstrating strong asset productivity, but the latest ROCE of 13.26% signals deteriorating capital efficiency. This decline warrants close monitoring, as it suggests that recent capital investments may not yet be generating proportionate returns. The company's substantial fixed asset base of ₹18,374.40 crores as of March 2026, though slightly reduced from ₹18,837.23 crores in the previous year, represents significant manufacturing and infrastructure investments that require time to deliver full operational leverage.
Capital Efficiency Watch
Whilst Mankind Pharma maintains healthy ROCE of 20.58% on average, the latest quarterly ROCE of 13.26% indicates pressure on capital productivity. The company's aggressive expansion, evidenced by high fixed asset base and rising employee costs, requires careful monitoring to ensure investments translate into improved returns. Management's ability to restore ROCE towards historical levels will be critical for sustaining investor confidence at current premium valuations.
The company's balance sheet exhibits mixed signals. Long-term debt stood at ₹2,821.23 crores as of March 2026, substantially reduced from ₹5,526.19 crores in the previous year, demonstrating strong deleveraging efforts. The debt-to-EBITDA ratio of 1.33 times remains comfortable, well within manageable limits, whilst the net debt-to-equity ratio of 0.26 indicates conservative leverage. This financial flexibility provides Mankind Pharma with capacity to fund growth initiatives without excessive balance sheet strain.
Working capital management showed improvement, with cash flow from operations reaching ₹3,121.00 crores for FY26, the highest in company history. However, closing cash declined to ₹391.00 crores from ₹403.00 crores, reflecting deployment of capital towards business expansion and debt reduction. Current assets of ₹6,954.20 crores comfortably exceeded current liabilities of ₹6,507.25 crores, maintaining adequate liquidity cushion.
Margin Dynamics: Cost Pressures Challenge Profitability
The pharmaceutical sector's margin dynamics have become increasingly challenging, and Mankind Pharma's Q1 FY27 results exemplify these pressures. The company's operating margin of 26.20%, whilst still healthy in absolute terms, represented a sequential decline from 27.01%, breaking a trend of margin expansion observed in previous quarters. This compression occurred despite strong revenue growth, indicating structural cost pressures rather than volume-related inefficiencies.
Employee costs emerged as the primary margin pressure point, surging to ₹913.50 crores and consuming 22.66% of revenues compared to 21.83% in Q4 FY26. This 83-basis-point increase in employee cost ratio reflects the company's ongoing investments in building sales force capabilities and strengthening organisational talent to support ambitious growth targets. Whilst necessary for long-term competitiveness, these investments compressed near-term margins.
Gross profit margin showed resilience, improving to 24.59% from 20.42% in Q3 FY26, though declining from 25.54% in Q4 FY26. This suggests reasonable pricing power and favourable product mix, though competitive intensity in the domestic formulations market limits significant margin expansion. The company's focus on chronic therapies and branded generics provides some insulation from pure commodity-like pricing pressures.
| Margin Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 | QoQ Change | YoY Change |
|---|---|---|---|---|---|
| Operating Margin (Excl OI) | 26.20% | 27.01% | 23.72% | -81 bps | +248 bps |
| Gross Profit Margin | 24.59% | 25.54% | 21.17% | -95 bps | +342 bps |
| PAT Margin | 14.24% | 16.25% | 12.45% | -201 bps | +179 bps |
| Employee Cost Ratio | 22.66% | 21.83% | 21.94% | +83 bps | +72 bps |
Looking ahead, margin trajectory will depend critically on the company's ability to leverage operating scale and control discretionary spending. The pharmaceutical industry's inherent operating leverage should enable margin recovery as revenue growth continues, provided cost inflation moderates. Management commentary around cost optimisation initiatives and operational efficiency programmes will be crucial indicators for investors monitoring margin sustainability.
Industry Leadership: How Mankind Pharma Compares to Peers
Within India's competitive pharmaceutical landscape, Mankind Pharma occupies a distinctive position as a leading domestic formulations player with strong brand equity. The company's market capitalisation of ₹1,06,503 crores positions it as the sixth-largest pharmaceutical company in the peer group, reflecting its substantial market presence. However, valuation metrics and profitability parameters reveal a nuanced competitive positioning that merits detailed examination.
| Company | Market Cap (₹ Cr) | P/E (TTM) | P/BV | ROE % | Debt/Equity | Div Yield % |
|---|---|---|---|---|---|---|
| Mankind Pharma | 1,06,503 | 52.71 | 6.53 | 15.98 | 0.26 | 0.04 |
| Divi's Laboratories | — | 79.34 | 12.42 | 16.32 | -0.20 | 0.38 |
| Torrent Pharma | — | 84.16 | 22.08 | 23.24 | 1.55 | 0.69 |
| Cipla | — | 33.04 | 3.43 | 14.00 | -0.24 | 0.89 |
| Lupin | — | 19.21 | 4.93 | 12.32 | -0.12 | 0.74 |
| Zydus Lifesciences | — | 20.40 | 4.10 | 17.49 | 0.20 | 0.09 |
Mankind Pharma's P/E ratio of 52.71 times positions it at a premium to value-oriented peers like Cipla (33.04x), Lupin (19.21x), and Zydus Lifesciences (20.40x), whilst trading at a discount to specialty players like Divi's Laboratories (79.34x) and Torrent Pharma (84.16x). This valuation reflects market recognition of the company's strong domestic franchise and growth potential, whilst acknowledging concerns about margin sustainability and competitive intensity.
The company's ROE of 15.98% places it in the middle of the peer group, superior to Cipla (14.00%) and Lupin (12.32%) but trailing Torrent Pharma (23.24%), Zydus Lifesciences (17.49%), and Divi's Laboratories (16.32%). This suggests room for improvement in capital productivity, particularly given the company's recent capacity expansion investments. The relatively modest dividend yield of 0.04% reflects management's preference for retaining capital to fund growth initiatives rather than distributing cash to shareholders.
Mankind Pharma's price-to-book value of 6.53 times appears reasonable compared to premium-valued peers like Torrent Pharma (22.08x) and Divi's Laboratories (12.42x), whilst commanding a significant premium over Cipla (3.43x) and Zydus Lifesciences (4.10x). This valuation differential reflects the market's assessment of franchise quality, growth prospects, and execution capabilities. The company's conservative leverage profile, with debt-to-equity of 0.26, provides financial flexibility that several highly-leveraged peers lack.
Valuation Analysis: Premium Pricing Demands Execution Excellence
Mankind Pharma's valuation metrics indicate the stock trades at elevated multiples that embed high growth expectations and quality premiums. The current P/E ratio of 52.71 times represents a substantial 42% premium to the pharmaceutical sector average of 37 times, signalling investor confidence in the company's growth trajectory and competitive positioning. However, this premium valuation leaves limited room for execution disappointments or margin surprises.
The price-to-book value of 6.53 times reflects market recognition of intangible assets including brand equity, distribution network, and market access capabilities that don't fully appear on the balance sheet. This multiple, whilst reasonable compared to specialty pharmaceutical peers, suggests investors are paying significantly above book value for future earnings potential. The EV/EBITDA multiple of 30.61 times and EV/EBIT of 40.54 times further confirm premium valuations across multiple metrics.
The PEG ratio of 35.28 appears extremely elevated, suggesting the stock may be overvalued relative to its growth rate. This metric warrants particular attention, as it indicates investors are paying ₹35.28 for every unit of earnings growth—well above the typically acceptable threshold of 2.0 or below. This elevated PEG ratio represents a significant valuation concern and limits upside potential unless the company can dramatically accelerate earnings growth.
The company's current market price of ₹2,576.95 trades just 3.49% below its 52-week high of ₹2,670.00, suggesting limited near-term upside from current levels. The stock has appreciated 34.93% from its 52-week low of ₹1,909.90, reflecting strong momentum over the past year. However, the year-to-date return of 17.33% has significantly outpaced the Sensex decline of 8.56%, generating alpha of 25.89%—a performance that may be difficult to sustain given valuation constraints.
Valuation Assessment: Very Expensive Territory
Mankind Pharma's valuation grade of "Very Expensive" reflects premium multiples across P/E, P/BV, and EV/EBITDA metrics. The stock has oscillated between "Expensive" and "Very Expensive" classifications over recent months, indicating valuation sensitivity to earnings performance and market sentiment. At current levels, the stock offers limited margin of safety and requires flawless execution to justify valuations. Any earnings disappointments or margin pressures could trigger significant valuation compression.
Shareholding: Institutional Confidence Building Gradually
The shareholding pattern of Mankind Pharma reveals a promoter-dominated structure with gradually increasing institutional participation. Promoter holding stood at 72.63% as of June 2026, marginally declining from 72.66% in March 2026 and 72.68% in June 2025. This minimal reduction of 5 basis points over the year reflects stable promoter commitment whilst allowing modest float expansion for institutional investors.
| Shareholder Category | Jun'26 | Mar'26 | Dec'25 | Sep'25 | QoQ Change |
|---|---|---|---|---|---|
| Promoter Holding | 72.63% | 72.66% | 72.66% | 72.67% | -0.03% |
| FII Holding | 9.45% | 10.24% | 11.34% | 12.84% | -0.79% |
| Mutual Fund Holding | 10.87% | 10.36% | 9.30% | 7.78% | +0.51% |
| Insurance Holdings | 1.54% | 1.14% | 1.12% | 1.77% | +0.40% |
| Other DII Holdings | 2.98% | 2.95% | 2.83% | 2.36% | +0.03% |
| Non-Institutional | 2.53% | 2.64% | 2.75% | 2.57% | -0.11% |
Foreign institutional investor (FII) holding declined to 9.45% from 10.24% in the previous quarter, continuing a concerning trend of sustained FII selling. Over the past year, FII holding has contracted from 13.07% to current levels, representing a reduction of 362 basis points. This persistent selling by foreign investors suggests concerns about valuation, growth sustainability, or broader emerging market allocation decisions. The presence of 501 FII holders indicates broad-based international interest, though aggregate positioning has declined.
Conversely, domestic mutual fund holding increased to 10.87% from 10.36%, marking the fourth consecutive quarter of accumulation. This 51-basis-point sequential increase and 353-basis-point year-on-year expansion from 7.34% demonstrates growing domestic institutional confidence. With 36 mutual funds holding stakes, the company enjoys diversified domestic institutional support. This divergence between FII selling and mutual fund buying suggests differing perspectives on valuation and growth prospects.
Insurance company holdings rose to 1.54% from 1.14%, a significant 40-basis-point increase, indicating long-term institutional investors are adding positions. Other domestic institutional investor (DII) holdings also expanded marginally to 2.98% from 2.95%. The combined domestic institutional holding (mutual funds + insurance + other DII) now stands at 15.39%, providing a stable investor base less susceptible to short-term sentiment shifts.
Promoter holdings are distributed across family trusts, with the Ramesh Juneja Family Trust holding 20.18%, Rajeev Juneja Family Trust at 19.35%, and Prem Sheetal Family Trust at 14.95%. Importantly, there is zero promoter pledging, eliminating concerns about forced selling or financial stress. This clean shareholding structure with no encumbered shares provides confidence in promoter financial stability and long-term commitment.
Stock Performance: Outperforming Markets Despite Recent Volatility
Mankind Pharma's stock performance over the past year presents a mixed picture of strong relative returns against the broader market, tempered by recent consolidation and sector underperformance. The stock's one-year absolute return of 0.56% appears modest in isolation but represents significant outperformance against the Sensex's decline of 4.36%, generating positive alpha of 4.92 percentage points.
| Period | Stock Return | Sensex Return | Alpha | Assessment |
|---|---|---|---|---|
| 1 Week | 0.78% | 2.01% | -1.23% | Underperformed |
| 1 Month | 1.20% | 1.90% | -0.70% | Slight lag |
| 3 Months | 14.71% | 1.32% | +13.39% | Strong outperformance |
| 6 Months | 21.27% | -5.28% | +26.55% | Exceptional alpha |
| YTD | 17.33% | -8.56% | +25.89% | Market-beating |
| 1 Year | 0.56% | -4.36% | +4.92% | Positive alpha |
| 2 Years | 25.34% | -4.33% | +29.67% | Substantial outperformance |
| 3 Years | 42.02% | 17.79% | +24.23% | Consistent alpha generation |
The stock's performance trajectory reveals distinct phases. Over the past three months, Mankind Pharma delivered exceptional returns of 14.71% against the Sensex's 1.32% gain, generating alpha of 13.39 percentage points. This outperformance accelerated over six months, with the stock advancing 21.27% whilst the Sensex declined 5.28%, producing remarkable alpha of 26.55 percentage points. These medium-term returns demonstrate strong momentum and investor confidence in the company's fundamentals.
However, recent short-term performance has moderated. Over the past week, the stock gained 0.78% compared to the Sensex's 2.01% advance, underperforming by 123 basis points. Similarly, the one-month return of 1.20% lagged the Sensex's 1.90% gain by 70 basis points. This recent underperformance coincides with the quarterly results announcement and suggests investors are reassessing growth expectations and margin sustainability.
Longer-term returns remain impressive, with two-year gains of 25.34% and three-year returns of 42.02%, both substantially outpacing the Sensex. The three-year alpha of 24.23 percentage points demonstrates consistent value creation for shareholders over an extended period. This track record of sustained outperformance provides confidence in management's execution capabilities and strategic direction.
Notably, the stock has underperformed its pharmaceutical sector peer group over the past year, with Mankind Pharma's 0.56% return trailing the sector's 11.52% advance by 10.96 percentage points. This sector underperformance suggests company-specific concerns or valuation constraints rather than broad industry tailwinds. Investors appear to favour other pharmaceutical companies with stronger margin profiles or clearer growth catalysts.
Technical indicators present a mixed picture. The stock trades above all key moving averages—5-day (₹2,568.82), 20-day (₹2,543.00), 50-day (₹2,472.05), 100-day (₹2,332.41), and 200-day (₹2,276.97)—indicating underlying strength. The overall technical trend classification of "Bullish" as of July 29, 2026, supports a constructive outlook, though weekly MACD shows bullish signals whilst monthly MACD indicates mildly bearish trends, suggesting potential near-term consolidation.
Investment Thesis: Quality Franchise at Premium Valuation
Mankind Pharma's investment thesis rests on a foundation of quality fundamentals, strong market positioning, and demonstrated execution capabilities, tempered by premium valuations and margin pressures. The company's Mojo score of 72 out of 100, upgraded from 58 in the previous assessment, reflects improving fundamentals and positive momentum across multiple parameters.
The quality assessment of "Good" reflects the company's strong competitive positioning, healthy balance sheet, and consistent profitability. Key quality indicators include average ROCE of 20.58%, average ROE of 15.98%, strong interest coverage of 27.35 times, and low leverage with debt-to-EBITDA of 1.33 times. The company has demonstrated healthy long-term growth with sales CAGR of 17.73% and EBIT CAGR of 20.15% over five years, indicating sustainable business model and market share gains.
The financial trend classification of "Positive" for Q1 FY27 highlights several encouraging developments. Operating cash flow reached an all-time high of ₹2,751.99 crores on an annual basis, demonstrating strong cash generation capabilities. The operating profit to interest coverage ratio reached a peak of 9.60 times, reflecting improved debt servicing capacity. Net sales and operating profit both achieved quarterly records, whilst earnings per share of ₹13.75 marked the highest quarterly EPS in company history.
However, the valuation assessment of "Very Expensive" represents a significant concern. The stock trades at P/E of 52.71 times, substantially above the industry average of 37 times, with an elevated PEG ratio of 35.28 indicating limited value relative to growth prospects. This premium valuation leaves minimal margin of safety and requires flawless execution to justify current multiples. Any disappointments in earnings growth or margin performance could trigger meaningful valuation compression.
The technical trend of "Bullish" provides near-term support, with the stock trading above all major moving averages and maintaining positive momentum indicators. However, conflicting signals between weekly bullish and monthly mildly bearish MACD readings suggest potential consolidation ahead. The stock's beta of 1.20 indicates higher volatility than the broader market, classifying it as a high-beta stock suitable for investors comfortable with above-average price fluctuations.
Key Strengths & Risk Factors
KEY STRENGTHS ✓
- Market Leadership: Commanding position in India's domestic pharmaceutical market with strong brand equity and extensive distribution network across therapeutic segments
- Strong ROCE: Average return on capital employed of 20.58% demonstrates efficient capital allocation and superior asset productivity compared to industry standards
- Healthy Growth: Five-year operating profit CAGR of 20.15% and sales CAGR of 17.73% reflect consistent market share gains and successful product portfolio expansion
- Low Leverage: Debt-to-EBITDA ratio of 1.33 times and net debt-to-equity of 0.26 provide financial flexibility and cushion against economic downturns
- Strong Cash Generation: Operating cash flow of ₹2,751.99 crores (annual) reached record levels, demonstrating robust cash conversion and working capital efficiency
- Clean Shareholding: Zero promoter pledging eliminates governance concerns, whilst stable 72.63% promoter holding indicates long-term commitment and alignment with minority shareholders
- Institutional Confidence: Growing domestic mutual fund and insurance holdings of 12.41% combined reflects increasing institutional conviction in growth prospects
KEY CONCERNS ⚠
- Margin Compression: Operating margin declined to 26.20% from 27.01% QoQ despite strong revenue growth, indicating structural cost pressures requiring management attention
- Rising Employee Costs: Employee expenses surged 21.54% QoQ to ₹913.50 crores, consuming 22.66% of revenues and pressuring profitability metrics
- Premium Valuation: P/E of 52.71 times and PEG ratio of 35.28 indicate expensive valuation with limited margin of safety for execution disappointments
- Deteriorating ROCE: Latest ROCE of 13.26% represents significant decline from historical average of 20.58%, raising concerns about capital productivity of recent investments
- FII Selling: Persistent foreign institutional investor selling reduced holdings from 13.07% to 9.45% over past year, suggesting international investor concerns
- Sector Underperformance: Stock's 0.56% one-year return trails pharmaceutical sector's 11.52% gain by 10.96 percentage points, indicating relative weakness
- Low Dividend Yield: Dividend yield of 0.04% provides minimal income component, with payout ratio of 2.16% indicating management preference for capital retention over distribution
Outlook: Key Monitoring Points
POSITIVE CATALYSTS
- Operating Leverage: Sustained revenue growth above 12-15% should enable margin recovery as fixed costs get absorbed over larger revenue base
- Product Pipeline: New product launches in chronic therapy segments could drive premium pricing and improve product mix, supporting margin expansion
- Market Share Gains: Continued outpacing of industry growth rates would validate competitive positioning and justify premium valuation multiples
- Debt Reduction: Further deleveraging below current levels would reduce interest burden and improve return ratios, enhancing financial flexibility
- Domestic Institutional Buying: Continued mutual fund and insurance accumulation could provide price support and offset FII selling pressure
RED FLAGS TO WATCH
- Sustained Margin Decline: Further compression in operating margins below 25% would signal structural profitability challenges requiring strategic reassessment
- ROCE Deterioration: Failure to restore ROCE towards 18-20% range within 2-3 quarters would indicate capital allocation concerns
- Continued FII Exodus: Persistent foreign institutional selling below 8-9% holdings could pressure valuations and limit upside potential
- Revenue Growth Slowdown: Quarterly revenue growth declining below 8-10% would undermine premium valuation justification and trigger multiple compression
- Competitive Intensity: Aggressive pricing actions by peers or market share losses in key therapeutic segments would challenge growth assumptions
The forward outlook for Mankind Pharma hinges critically on management's ability to restore margin trajectory whilst maintaining revenue momentum. The pharmaceutical industry's inherent operating leverage should enable margin recovery as topline growth continues, provided employee cost inflation moderates and operational efficiencies materialise. Investors should monitor quarterly margin trends closely, with particular focus on employee cost ratios and operating profit margins.
The company's capacity to improve return on capital employed from current depressed levels of 13.26% towards historical averages of 20% will be crucial for sustaining investor confidence. This requires that recent capital investments in manufacturing facilities, sales force expansion, and infrastructure begin generating proportionate returns. Management commentary around capacity utilisation rates, productivity improvements, and return on incremental capital will provide important signals.
Valuation remains the primary constraint on near-term upside potential. At current multiples, the stock offers limited margin of safety and requires sustained high-teens earnings growth to justify valuations. Any disappointments in quarterly results, margin performance, or growth rates could trigger significant valuation compression. Conversely, successful margin restoration and accelerated earnings growth could support current valuations, though further multiple expansion appears unlikely without extraordinary performance.
The Verdict: Quality Franchise Warranting Selective Accumulation
Score: 72/100
For Fresh Investors: Consider initiating positions in 2-3 tranches, targeting entry on any 5-8% corrections from current levels. The quality of the franchise and improving fundamentals support a BUY rating, though premium valuations warrant patience for better entry points. Suitable for investors with 3-5 year investment horizon comfortable with pharmaceutical sector dynamics and moderate volatility.
For Existing Holders: Maintain positions with conviction. The improving Mojo score, positive financial trends, and bullish technical setup support continued holding. Use any sharp corrections as opportunities to average up positions, particularly if margins show signs of stabilisation. Consider booking partial profits if stock approaches ₹2,750-2,800 levels representing 7-9% upside.
Fair Value Estimate: ₹2,450-2,550 (4.9% downside to 1.0% downside from current price of ₹2,576.95). Current trading range appears fairly valued to slightly expensive. Significant upside requires margin restoration and sustained high-teens earnings growth.
Note: ROCE = (EBIT - Other income) / (Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance does not guarantee future results. Investments in equity markets are subject to market risks, and investors may lose part or all of their capital.
